This trial will measure the safety and efficacy of a drug given to people with systemic sclerosis over a year.
- Systemic Sclerosis
- Progressive Systemic Sclerosis
11 Primary · 0 Secondary · Reporting Duration: Day 1 to Week 56
Awards & Highlights
1 Treatment Group
1 of 1
300 Total Participants · 1 Treatment Group
Primary Treatment: HZN-825 · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there still opportunities for participants to join this experiment?
"That is accurate. According to information on clinicaltrials.gov, this medical trial which was initially published on November 4th 2022, continues seeking participants actively. 300 people need to be recruited at 1 centre for the study's completion." - Anonymous Online Contributor
Has the FDA granted clearance to HZN-825?
"Our team has assessed HZN-825's safety to be a 2, as there is some documentation confirming the medication's security but no clinical evidence of its efficacy." - Anonymous Online Contributor
How many individuals have opted to take part in this experiment?
"Affirmative. Clinicaltrials.gov displays that this clinical trial is presently seeking participants, with the initial posting occurring on November 4th 2022 and an update made on November 15th 2022. 300 individuals must be enrolled from 1 site in total." - Anonymous Online Contributor